The DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Oseltamivir (Tamiflu®) and its potential for use in the event of an influenza pandemic
Open accessAbstract
Recent cross species transmission of avian influenza has highlighted the threat of pandemic influenza. Oseltamivir (Tamiflu) has been shown to be effective in the treatment and prevention of epidemic influenza infection in adults, adolescents and children (> or = 1 year). Although oseltamivir has not been approved for prophylactic use in children, it has been shown to be effective. Oseltamivir is also active against avian influenza virus strains. Evidence suggests that lower doses or shorter durations of treatment/chemoprophylaxis other than those approved may not be effective and may contribute to emergence of viral resistance. Safety data from dose ranging studies show that 5 day courses of 150 mg twice daily for treatment and 6 week courses of 75 mg twice daily for prophylaxis were as well tolerated as the approved dose regimens. The use of oseltamivir in a pandemic is influenced by the goals of the pandemic plan developed by the responsible Government and Health Authority. To optimize use of antiviral medications, processes will be needed to collect, collate and report outcome data from treated patients and/or from use for chemoprophylaxis of pandemic influenza during the first-wave outbreaks. If oseltamivir is included in a national or regional pandemic plan, stockpiling of the material, either in the form of capsules or the bulk active pharmaceutical ingredient will be necessary. In the absence of a stockpile, there is no guarantee that an adequate supply of oseltamivir will be available.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
THE STRUCTURE AND FUNCTION OF THE HEMAGGLUTININ MEMBRANE GLYCOPROTEIN OF INFLUENZA VIRUS
Wiley, D. C., & Skehel, J. J. (1987) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.56.070187.002053 · Cited by 1,415
Treanor, J. J., Hayden, F. G., Vrooman, P. S., Barbarash, R., Bettis, R., Riff, D., Singh, S., Kinnersley, N., Ward, P., Mills, R. G., et al. (2000) · JAMA · doi:10.1001/jama.283.8.1016 · Cited by 1,014
Self-citationAvian Influenza A (H5N1) in 10 Patients in Vietnam
Hien, T. T., Liem, N. T., Dung, N. T., San, L. T., Mai, P. P., Chau, N. V. V., Suu, P. T., Dong, V. C., Mai, L. T. Q., Thi, N. T., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040419 · Cited by 839
Koopmans, M., Wilbrink, B., Conyn, M., Natrop, G., van der Nat, H., Vennema, H., Meijer, A., van Steenbergen, J., Fouchier, R., Osterhaus, A., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)15589-x · Cited by 837
Potier, M., Mameli, L., Bélisle, M., Dallaire, L., & Melançon, S. B. (1979) · Analytical Biochemistry · doi:10.1016/0003-2697(79)90362-2 · Cited by 815
Characterization of temperature sensitive influenza virus mutants defective in neuraminidase
Palese, P., Tobita, K., Ueda, M., & Compans, R. W. (1974) · Virology · doi:10.1016/0042-6822(74)90276-1 · Cited by 789
Resistant influenza A viruses in children treated with oseltamivir: descriptive study
Kiso, M., Mitamura, K., Sakai-Tagawa, Y., Shiraishi, K., Kawakami, C., Kimura, K., Hayden, F. G., Sugaya, N., & Kawaoka, Y. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16934-1 · Cited by 786
Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial
Nicholson, K., Aoki, F., Osterhaus, A., Trottier, S., Carewicz, O., Mercier, C., Rode, A., Kinnersley, N., & Ward, P. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02288-1 · Cited by 785
Self-citationHayden, F. G., Osterhaus, A. D. M. E., Treanor, J. J., Fleming, D. M., Aoki, F. Y., Nicholson, K. G., Bohnen, A. M., Hirst, H. M., Keene, O., & Wightman, K. (1997) · New England Journal of Medicine · doi:10.1056/nejm199709253371302 · Cited by 762
Initial Genetic Characterization of the 1918 “Spanish” Influenza Virus
Taubenberger, J. K., Reid, A. H., Krafft, A. E., Bijwaard, K. E., & Fanning, T. G. (1997) · Science · doi:10.1126/science.275.5307.1793 · Cited by 715
Cited by
H1N1 2009 influenza virus infection during pregnancy in the USA
Jamieson, D. J., Honein, M. A., Rasmussen, S. A., Williams, J. L., Swerdlow, D. L., Biggerstaff, M. S., Lindstrom, S., Louie, J. K., Christ, C. M., Bohm, S. R., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61304-0 · Cited by 1,361
Avian Influenza A (H5N1) Infection in Humans
(2005) · New England Journal of Medicine · doi:10.1056/nejmra052211 · Cited by 1,285
Avian Influenza Virus (H5N1): a Threat to Human Health
Peiris, J. S. M., de Jong, M. D., & Guan, Y. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00037-06 · Cited by 1,007
Oseltamivir Resistance during Treatment of Influenza A (H5N1) Infection
de Jong, M. D., Thanh, T. T., Khanh, T. H., Hien, V. M., Smith, G. J. D., Chau, N. V., Cam, B. V., Qui, P. T., Ha, D. Q., Guan, Y., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa054512 · Cited by 901
The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design
Russell, R. J., Haire, L. F., Stevens, D. J., Collins, P. J., Lin, Y. P., Blackburn, G. M., Hay, A. J., Gamblin, S. J., & Skehel, J. J. (2006) · Nature · doi:10.1038/nature05114 · Cited by 813
Transmission of influenza A in human beings
Brankston, G., Gitterman, L., Hirji, Z., Lemieux, C., & Gardam, M. (2007) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(07)70029-4 · Cited by 744
Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children
Jefferson, T., Jones, M. A., Doshi, P., Del Mar, C. B., Heneghan, C. J., Hama, R., & Thompson, M. J. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008965.pub3 · Cited by 594
Infections With Oseltamivir-Resistant Influenza A(H1N1) Virus in the United States
Dharan, N. J. (2009) · JAMA · doi:10.1001/jama.2009.294 · Cited by 527
Sheu, T. G., Deyde, V. M., Okomo-Adhiambo, M., Garten, R. J., Xu, X., Bright, R. A., Butler, E. N., Wallis, T. R., Klimov, A. I., & Gubareva, L. V. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00555-08 · Cited by 480
Continuing challenges in influenza
Webster, R. G., & Govorkova, E. A. (2014) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12462 · Cited by 399
Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance
McKimm‐Breschkin, J. L. (2013) · Influenza and Other Respiratory Viruses · doi:10.1111/irv.12047 · Cited by 390
Neuraminidase inhibitors for preventing and treating influenza in adults and children
Jefferson, T., Jones, M. A., Doshi, P., Del Mar, C. B., Hama, R., Thompson, M. J., Spencer, E. A., Onakpoya, I. J., Mahtani, K. R., Nunan, D., et al. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008965.pub4 · Cited by 382
Monto, A. S., McKimm-Breschkin, J. L., Macken, C., Hampson, A. W., Hay, A., Klimov, A., Tashiro, M., Webster, R. G., Aymard, M., Hayden, F. G., et al. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01339-05 · Cited by 364
Oseltamivir-Resistant Influenza Virus A (H1N1), Europe, 2007–08 Season
Meijer, A., Lackenby, A., Hungnes, O., Lina, B., van der Werf, S., Schweiger, B., Opp, M., Paget, J., van de Kassteele, J., Hay, A. J., et al. (2009) · Emerging infectious diseases · doi:10.3201/eid1504.081280 · Cited by 362
Influenza virus resistance to neuraminidase inhibitors
Samson, M., Pizzorno, A., Abed, Y., & Boivin, G. (2013) · Antiviral Research · doi:10.1016/j.antiviral.2013.03.014 · Cited by 343
Pandemic Influenza and Pregnant Women
Rasmussen, S. A., Jamieson, D. J., & Bresee, J. S. (2008) · Emerging Infectious Diseases · doi:10.3201/eid1401.070667 · Cited by 343
Structure of influenza hemagglutinin in complex with an inhibitor of membrane fusion
Russell, R. J., Kerry, P. S., Stevens, D. J., Steinhauer, D. A., Martin, S. R., Gamblin, S. J., & Skehel, J. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0807142105 · Cited by 314
Antivirals for influenza in healthy adults: systematic review
Jefferson, T., Demicheli, V, Rivetti, D., Jones, M., Di Pietrantonj, C., & Rivetti, A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)67970-1 · Cited by 286
Developing New Antiviral Agents for Influenza Treatment: What Does the Future Hold?
Hayden, F. (2009) · Clinical Infectious Diseases · doi:10.1086/591851 · Cited by 256
Antiviral Resistance and the Control of Pandemic Influenza
Lipsitch, M., Cohen, T., Murray, M., & Levin, B. R. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040015 · Cited by 209
“Of those blocked infections, a proportion ap are only partially blocked, so that the prophylaxed individual becomes immune, but does not become sick or infectious to others [17]; such individuals move directly to the recovered (Z) category.”
Background
Metadata
- Authors
- Ward, P., Small, I., Smith, J., Suter, P., & Dutkowski, R.
- Venue
- Journal of Antimicrobial Chemotherapy
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-02-01
- Volume
- 55
- Issue
- suppl_1
- Pages
- i5-i21
- ISSN
- 0305-7453 (ISSN-L)
- 1460-2091
- OpenAlex
- W2117004115
- Cited by
- 428
- References
- 69
- FWCI
- 27.27
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.